Standard Serum Concentrations and Normal Fluctuations of CEA, CA 50 and CA 242 during Twelve Months in Men and Women Aged 60-64 years without Malignant Disease

References

• Arnaud JP, Koehl C, Adloff M. CEA in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 1980; 23: 141–144.
   PubMed Web of Science ®Google Scholar
• Barillari P. Bolognesi A, Chirletti P. Cardi M, Sammartino P. Stipa V. Role of CEA, TPA, and CA 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum 1992; 35: 471–476.
   Google Scholar
• Beatty JD, Romero C, Brown PW, Lawrence Jr W, Terz B. Clinical value of carcinoembryonic antigen. Arch Surg 1979; 114: 563–567.
   Google Scholar
• Carpeland-Holmstrom M, Haglund C, Lundin J, Alfthan H, Stenman U-H, Roberts PJ. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gona-dotrophin beta, but not of CEA or tissue polypeptide antigen in colorectal cancer. Br J Cancer 1996; 74: 926–929.
   Google Scholar
• Clarke CS, Hine KR, Dykes PW, Whitehead TP, Whitfield AGW. Carcinoembryonic antigen and smok-ing. J R Coll Physicians (Lond) 1980; 14: 227–228.
   PubMedGoogle Scholar
• Eskelinen M, Pasanen P. Kulju A, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994; 14: 1427–1432.
   PubMed Web of Science ®Google Scholar
• Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66–73.
   Google Scholar
• Habib NA, Hershman MJ, Smadja C, Wood CB. The use of CA 50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant liver disease. Br J Surg 1986; 73: 758–759.
   Google Scholar
• Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994; 70: 487–492.
   PubMed Web of Science ®Google Scholar
• Haglund C, Roberts PJ, Jalankko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27: 169–174.
   PubMed Web of Science ®Google Scholar
• Haines AP, Levin AG, Fritsche HA. Ethnic group differences in serum levels of carcinoembryonic anti-gene (letter). Lancet 1979; 2: 969.
   Google Scholar
• Hall NR, Finan PJ, Stephenson BM, Purves DA, Cooper EH. The role of CA 242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 1994; 70: 549–553.
   PubMed Web of Science ®Google Scholar
• Herbeth B, Bagrel A. A study of factors influencing plasma levels in an unselected population. Oncodev Biol Med 1980; 1: 191–198.
   PubMedGoogle Scholar
• Hohenberger P. Schlag PM, Gemeth T, Herfarth C. Pre-and postoperative carcinoembryonic antigen determina-tions in hepatic resections for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg 1994; 219: 135–143.
   Google Scholar
• Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and CEA in digestive tract disease. Br J Cancer 1991; 63: 636–640.
   Google Scholar
• Lewi H, Blumgart LH, Carter DC, et al. Pre-operative carcino-embryonic antigen and survival in patients with colorectal cancer. Br J Surg 1984; 71: 206–208.
   Google Scholar
• Lopez LA, Del Villar V, Ulla M, et al. Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 1996; 25: 45–50.
   PubMed Web of Science ®Google Scholar
• Matsouka Y, Endo K, Kawamura Y, et al. Normal bronchial mucus contains high levels of cancer-asso-ciated antigens, CA 125, CA 19-9 and carcinoembryonic antigen. Cancer 1990; 65: 506–510.
   Google Scholar
• Nilsson 0, C J, Glimelius B, et al. Sensitivity and specificity of CA 242 in gastro-intestinal cancer. A comparison with CEA, CA 50 and CA 19–9. Br J Cancer 1992; 65: 215–221.
   Google Scholar
• Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P. Penttild I, Alhava E. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study. Anticancer Res 1992; 12: 1689-1694.
   Google Scholar
• Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monotoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996; 16: 2249–2252.
   PubMed Web of Science ®Google Scholar
• Slentz K, Senagore A, Hibbert J, Mazier WP, Talbott TM. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg 1994; 60: 528–531.
   Google Scholar
• Staab HJ, Anderer FA, Stumpf E, Fischer R. CEA follow-up and selection of patients for second-look operation in management of gastrointestinal carcinoma. J Surg Oncol 1978; 10: 273–282.
   PubMed Web of Science ®Google Scholar
• Stale E. Prognostic indicators in rectal carcinoma. An evaluation of clinicopathological variables, tumour markers and tumour stage. [Thesis]. Uppsala, Sweden, 1988.
   Google Scholar
• Tabor E, Gerety RJ, Needy CF, Elisberg BL, Colon AR, Jones R. CEA levels in asymptomatic adolescents. Eur J Cancer 1981; 17: 257–258.
   Google Scholar
• Touitou Y, Proust J, Klinger E, Nakache J-P, Huard D, Sachet A. Cumulative effects of age and pathology on plasma CEA in an unselected elderly population. Eur J Cancer Clin Oncol 1984; 20: 369–371.
   Google Scholar
• Verazin G, Riley WM, Gregory J, Tautu C, Prorok J, Alhadeff JA. Serum sialic acid and carcinoembryonic levels in the detection and monitoring of colorectal cancer. Dis Colon Rectum 1990; 33: 139–142.
   Google Scholar
• Wang JY, Tang R, Chiang JM. Value of carcinoem-bryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994; 37: 272–277.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Cohen AM, Urmacher C. Usefulness of CEA monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993; 36: 1063–1068.
   Google Scholar